Market Research Blog

According to International Agency for Research on Cancer, the number of new cancer cases per year is expected to rise to 23.6 million by 2030 globally. In recent times, cell line development and its applications are considered as potential tools in oncology research. Cell lines are projected to be used for development of new treatment pathway for various disease including cancer and neurological diseases. According to a latest research by Future Market Insights (FMI), the global cell line development market size is anticipated to account for over US$ 7,200 Mn, in terms of value, by 2028 end. The report on cell line development market further projects significant growth potential with CAGR at 7.2% through 2028.

Rapid increase in prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.

Download the sample copy of Report with table of contents and Figures : https://www.futuremarketinsights.com/reports/sample/rep-gb-7566

In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST). Regenerative medicines are the next generation treatment solution and Cell Line Development or Cell Culture is a vital part for regenerative medicine. Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period.

The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market.

Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, type of cell line and region.

Preview Analysis of Cell Line Development Market: Reagents and Media Segment Anticipated to be the Most Attractive During the Forecast Period: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028: https://www.futuremarketinsights.com/reports/cell-line-development-market

Product type segment in cell line development market is segmented into media and reagents, equipment and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. Reagent and media segment in cell line development market is expected witness noteworthy growth in terms of revenue owing to rapid increase in demand in cell culture and cell based assays.

Cell line development market by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipate to witness significant growth in overall cell line development market. This growth of mammalian cells segment in cell line development market is driven by increased production of biologics drugs which require mammalian cells. Increasing antibody production is the major driving factor behind the growth of mammalian cell lines segment in cell line development market. Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection.

For example, Gaucher’s disease, which is a genetic disorder characterized by lack of β-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produces in mammalian cell lines. Mammalian cell lines are also useful in production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease causing agents in the body.

Buy this report @ https://www.futuremarketinsights.com/checkout/7566

For example Under cell line type segment in cell line development market, recombinant cell line development are the most demanding type of cell line due to large application in biologics production, protein interaction, gene activation, toxicity testing and drug screening. Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period

North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market. The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.

FMI’s report tracks some of the key companies operating in the cell line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-7566

As per ESOMAR-certified consulting firm Future Market Insights (FMI), the global companion animal specialty drugs market registered steady year-on-year (YoY) growth at 5.42% CAGR in 2021.

Increasing pet adoption is a major factor, fuelling the demand for animal nutrition and behavioural products, thereby accelerating sales. With increasing rate of obesity among the pet, demand for anti-obesity drugs have burgeoned over the past few years.

Adoption of canine and feline pets increased during the FQ-20, due to the outbreak of COVID-19 and consequent global shutdown. Adoption of dogs is quite high, especially among the geriatric population. This is expected to drive the demand for antibiotics, skin-care, and nutritional products for pets.

As per FMI, the market is expected to reach a valuation of US$ 36,104.66 Mn in 2021 owing to the increasing demand for anti-obesity drugs across veterinary clinics. Alongside this, prevalence of canine vector-borne diseases due to bacteria and protozoa infection will fuel the demand for parasiticides in the next decade.

Key Takeaways from FMI’s Companion Animal Specialty Drugs Market Study

• By product type, parasiticides will dominate the market, accounting for over 32%of global market share.
• In terms of distribution channel, veterinary clinics are expected to lead the segment contributing over 52%of value share by 2031
• In terms of technology type, drying technology is predicted to exceed US$ 89 Bnby end 2031
• The U.S. will emerge as the leading market across North America backed by the high adoption of pet dogs
• Germany and the U.K. are anticipated to lead the Europe’s Companion animal specialty drugs market, owing to the growing obesity rate in dogs
• Increasing cases of neglect and animal cruelty in India will bolster the demand for companion animal specialty drugs through 2021

Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3984

“The demand for compounded medications and anti-obesity drugs for animals will continue increasing in the coming years. This has encouraged some of the leading companies to focus on research initiatives to launch novel drugs to facilitate improved care for companion animals. This will create impressive growth opportunities in the coming years,” says the FMI analyst.

Competitive Landscape

Zoetis Inc., Merck and Co., Inc., Bayer AG, Eli Lily and Co. and Boehringer Ingelheim GmbH are the key players operating in the companion animal specialty drugs market. among others are some prominent players operating in the Companion animal specialty drugs market.

For instance, in July 2020, Boehringer Ingelheim announced the launch of two new products, NexGard and Broadline, to provide comprehensive parasite treatment for dogs and cats, to expand their product portfolio for the India market.

As per the report, key players are focusing on product introduction and launches to expand their product portfolios. Key player are also involved extensively in strategic acquisition activities which has led to severe competition among companion animal specialty drugs market players.

For example, on August 4,2021, Zoetis, the Parsippany-based animal health company announced the acquisition of a leading Australian-based Jurox’s veterinary medicines, maker of livestock and companion animal medicines.

What else is in the report?

Future market insights offers a unique perspective and actionable insights on companion animal specialty drugs market in its latest study, presenting historical demand assessment from 2016 – 2020 and projections from 2021-2031 based on product type (antibiotics, anti-inflammatory drugs, parasiticides, heartworm, behavioral products, nutritional products, anti-obesity drugs, skin care products and vaccines), distribution channel (veterinary hospitals, veterinary clinics and pharmacies and drug stores) in seven key regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Speak to Analyst, Questions Related To Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-3984

Key Questions Answered in the Report

• What is the current companion animal specialty drugs market value?

The companion animal specialty drugs market is expected to exceed US$36,104.66 Mn in 2021

• At what rate did the companion animal specialty drugs market grow between 2016 and 2020?

The companion animal specialty drugs market projected steady growth, registering a CAGR at 5.43% between 2016 and 2020.

• What are the key trends driving companion animal specialty drugs distribution?

Growing demand for compounded medications and increasing adoption of anti-obesity drugs to reduce the growing obesity rate among pets will drive the sales.

• Who are the leading players of companion animal specialty drugs?

Zoetis Inc., Merck and Co., Inc., Bayer AG, Eli Lily and Co. (Elanco), Merial (Sanofi), Ceva Santé Animale, Virbac Animal Health, and Boehringer Ingelheim GmbH, are the top players FMI identifies as key players.

• What will be the demand outlook for North America companion animal specialty drugs market?

North America’s companion animal specialty drugs market demand is set to rise at over 3.38% CAGR during the forecast period of 2021 and 2031.

• What is the market share of leading players in Companion animal specialty drugs market?

The top 10 players in the companion animal specialty drugs market will collectively account for over 85% of global market share in the year 2021.

 

Sales of smart pill boxes and bottles are likely to reach around 800 thousand in 2019. According to a new analytical research study by Future Market Insights (FMI), smart pill boxes and bottles market will remain a high growth-low volume landscape over the course of next few years. Over 43% of total sales will be accounted by smart pill boxes. The report envisages a higher rate of adoption for smart pill bottles.

Almost 70% of adult patients are observed to discontinue or manipulate drug therapy, resulting in non-adherence to prescribed medication. The study opines that this directly adds to the economic burden on healthcare delivery system in form of emergency cases and hospitalization.

Smart pill boxes and bottles are increasingly being perceived as a potential solution to such challenges posed by increased healthcare delivery costs. Significance of medication adherence continues to rise with increasing prevalence of chronic conditions, propelling demand for smart pill boxes and bottles.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1710

Dementia and geriatric care remain the key application areas of smart pill boxes and bottles, according to the report. More than 80% of sales is accounted by aging patients and dementia-afflicted population. Cancer management is likely to emerge lucrative in terms of applicability in coming years.

With surging demand for high-quality healthcare delivery, senior care centers, hospitals, long-term care centers, and homecare settings are accelerating adoption of medication dispensers, thereby elevating the revenue growth of smart pill boxes and bottles market. Some of the leading companies are actively involved in the development of advanced technology medication dispensing devices with zero error risks during medication.

Buy this report @ https://www.futuremarketinsights.com/checkout/1710

Home care settings maintain the highest consumption share in smart pill boxes and bottles market that roughly equates 65% of total sales. Almost a fifth of smart pill boxes and bottles sold are installed at seniors care and assisted living centers. FMI’s analysis indicates that long-term care centers are also creating promising market opportunities for smart pill boxes and bottles manufacturers and distributors.

North America continues to reign supreme owing to early adoption of advanced technology enabled smart pill boxes and bottles, accounting for more than a third of the global market revenue. European market for smart pill boxes and bottles also represents a substantial volume share, majorly driven by German patients. South and East Asian regions are briskly developing high-potential markets for manufacturers and distributors of smart pill boxes and bottles, says the report.

Preview Analysis of Smart Pill Boxes & Bottles Market is segmented by (Type – Smart Pill Box & Smart Pill Bottles; Indication – dementia, Parkinson’s disease, cancer management, diabetes care, geriatric care, disability & others; Distribution channel – seniors care & assisted living, long term care centers & home care;) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028: https://www.futuremarketinsights.com/reports/smart-pill-boxes-bottles-market

The vendor landscape of smart pill boxes and bottles market remains fairly consolidated and competitive, as Tier 1 manufacturers continue to account for a majority of share in the market in terms of volume. While dominance of Koninklijke Philips N.V., PharmRight Corporation & Livi, and AdhereTech prevails in smart pill boxes and bottles market, the report finds that the competition among these players is characterized by product innovation, new launches, and technological advancements.

FMI has tracked market performance for a decade-old projection period – 2018-2028. For exclusive insights on the various other aspects of smart pill boxes and bottles market landscape, write to the analyst at press@futuremarketinsights.com

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1710

More from Healthcare, Pharmaceuticals and Medical devices Market Insights Market Intelligence:

• Skin Tears Treatment Market Analysis – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028
• Lung Pulmonary Airway Disease Treatment Market Analysis – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017-2027
• Handheld Arthroscopic Instruments Market Analysis – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028

The rapidly increasing prevalence of chronic diseases around the world is expected to fuel the need for novel drugs and better treatment option would further drive the growth of the global market. Due to increasing demand for novel drugs option, there has been rising applications of drug intermediates and growing adoption and in the field of research and clinical studies.

Get | Download Sample Copy with Graphs & List of Figures:
https://www.futuremarketinsights.com/reports/sample/rep-gb-4515

Patients suffering from OA have a lower-than-normal concentration of HA in their joints. Injecting HA lubricates bones to move smoothly over each other. Viscosupplementation facilitates movement and reduces pain in the arthritic joint. It is often recommended when other nonsurgical treatment methods have failed to provide positive outcomes.

Future Market Insights (FMI) delivers key insights on the Europe viscosupplementation market in its upcoming report titled, “Viscosupplementation Market: Europe Industry Analysis and Opportunity Assessment, 2016-2026”. In terms of revenue, the Europe viscosupplementation market is projected to register a healthy CAGR of 5.1% during 2016-2026.

FMI’s report has segmented the market on the basis of product type, end user and region.

Based on product type, the market has been segmented into one injection viscosupplementation, three injection viscosupplementation and five injection viscosupplementation.

Single injection viscosupplementation product type segment is expected to emerge as the most popular segment over the forecast period, driven by better patient compliance as the treatment reduces the need for multiple hospital visits. The segment is expected to register the highest CAGR of 6.7% during the forecast period.

Request Free Report Sample@ www.futuremarketinsights.com/reports/sample/rep-eu-1383

Five injection viscosupplementation product type segment is expected to witness a decline in market share in terms of revenue from 29.0% in 2015 to 23.3% in 2026. This decline is attributed to more incidence of side effects and repeated patient visit requirements associated with five injection viscosupplementation. Reimbursement cutbacks and high injection costs are other factors that can curtail demand for five injection viscosupplementation.

By end-users, the market is segmented into hospitals, ambulatory surgical centres and orthopaedic clinics. Hospitals end-use segment is expected to witness significant demand for viscosupplementation, registering a CAGR of 4.3% over the forecast period. Better reimbursement options and increasing patient preference for single injection cycle for osteoarthritis treatment is expected to drive demand for one injection viscosupplementation in the orthopaedic clinics segment over the forecast period.

Europe Viscosupplementation Market Trends

Key trends in the viscosupplementation market are the use of single injection cycle for osteoarthritis treatment and introduction of new combination products in the market. For example, the product pipeline of major players in the viscosupplementation market involves combining corticosteroid injections, which help in relieving pain associated with osteoarthritis, with long-lasting effects of hyaluronic acid, which lasts for nearly six months. Further, regional competition within EU countries, especially in five injection cycle, is leading to entry of new market players. Europe is a mature market in terms of generic products and it is therefore relatively easier to obtain CE mark in Europe than it is to obtain the U.S. FDA approval.

Western Europe has been estimated to dominate the Europe viscosupplementation market in 2015, attributed to factors such as the presence of key regional players, strong distribution network and better healthcare infrastructure in the region.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-eu-1383

Key Players in Europe Viscosupplementation Market

Some key players in the Europe viscosupplementation market are Anika Therapeutics Inc., Sanofi S.A., Zimmer Biomet Holdings, Meda AB, Ferring B.V, Fidia Pharmaceutici S.p.A, and Bioventus LLC. We have discussed individual strategies followed by these companies in terms of enhancing product designs, creating new manufacturing facilities, market consolidation and advanced R&D initiatives. The report concludes with key takeaways that could help players already present in the market and new players planning to enter the market in the long run.

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape

Foley Catheter Market FMI’s report analyses segmentation on the basis of form, type and end-use etc. Market trends, economic factors are taken into consideration for a clear analysis.

Thermodilution Catheter Market Find insights on market trends, strategies, historical and forecast data estimations and geographical regions exhibiting promising growth.

Empty capsules are witnessing an adoption upsurge, owing to numerous factors such as limited number of competitors, growing demand from the pharmaceutical sector, standard margin level, and potential opportunities in vegan gelatin-based capsules. Further, faster uptake by the FDA and focus of market players on ramping up production capacity are key factors shaping the growth of the empty capsules market.

Get | Download Sample Copy with Graphs & List of Figures:
https://www.futuremarketinsights.com/reports/sample/rep-gb-782

An increasing number of companies within the pharmaceutical sector have been considering contract manufacturing in response to the increasing demand for generic drugs and biologics. In a new study, Future Market Insights (FMI) has forecast the global contract manufacturing/ contract development and manufacturing organization (CMO/ CDMO) market to surpass US$ 18 Bn by 2020.

Get | Download Sample Copy with Graphs & List of Figures:
https://www.futuremarketinsights.com/reports/sample/rep-gb-13038

According to the study, contract manufacturing accounts for 3/4^th of all the CMO and CDMO services. Focus towards cost management, enhanced process flow, and better scalability will drive the market over the forecast period. Besides this, the increasing demand for skin care products, which also accounts for the leading share in terms of product type, will enable the market gain impetus in the coming years.

Currently an increasing number of consumers are shifting towards locally sourced and natural products rather than big brands. Achieving this will require state-of the-art technology besides other resources. As a result an increasing number of pharmaceutical companies are seeking services of contract manufacturing / contract development and manufacturing organization (CMO/CDMO).

Ask Us Your Questions About This Report:
https://www.futuremarketinsights.com/ask-question/rep-gb-13038

Key Takeaways from CMO/CDMOs Market Study

• CMO/ CDMO services has become highly sought-after in pharmaceutical and beauty industries. FMI has projected the market to report 6.2% CAGR between 2020 and 2030
• The U.S. is expected to account for over 77% of sales in North America by 2030
• The U.K. will represent impressive scope for expansion, exhibiting above 7% CAGR through the forecast period
• The rising focus on healthcare and wellness spending will support growth in Germany and France
• The availability of inexpensive labor and resources will continue supporting growth in China. However, Japan and South Korea markets are expected to register higher percentage of growth over the forecast period

“Manufacturers operating in the market are keen on forging strategic partnerships with leading cosmetics brands and pharmaceutical companies. Collaborations are expected to remain a primary strategy adopted by market players to gain competitive edge,” says FMI analyst

In terms of the effect of COVID-19 pandemic on the demand of CMO/CDMO services, there was a negative impact on the market growth. One of the major issues was related to the supply chain gap. Prior to COVID-19, contract manufacturing was one of the most preferred sectors in the growing beauty and personal care industry. However, due to the pandemic, the industry suffered major setbacks as expected product launches were delayed. A shift was observed in consumer habits. Reduction of sales of leading products was recorded along with production slowdowns, which caused overhead to curb the profitability.

For More Information or Query or Customization Before Buying, Visit:
https://www.futuremarketinsights.com/customization-available/rep-gb-13038

Who is Winning?

Collaboration is the key strategy amongst market players. The CMO/CDMO companies continue to focus on collaborations to gain sustainability in the market.

• For instance, In February 2021, Lonza signed an agreement to divest its specialty ingredients business to Bain Capital and Cinven, aiming to refocus as a pure-play partner to the healthcare industry.

• In 2021, Pierre Fabre Group hosted a pioneering custom online partnering forum, partnering with biopharmaceutical firms aiming to accelerate the digital transformation of Pierre Fabre Group
• In 2020, In March 2020, Pierre Fabre Group, in partnership with numerous hospitals in the Occitania region of France, donated hand care creams, body cleansing gels and thermal spring water sprays and hand sanitizers necessary to combat the spread of Covid-19.

Increasing adoption of label-free detection techniques over labelled detection techniques is due to their cost-effective nature. Additionally, the availability of versatile products coupled with surface plasmon resonance to enhance the specificity of tests is an important factor that will bolster the demand for surface plasmon resonance. Imaging systems help in increasing throughput at a remarkable speed and with precise motion and consistency in report generation. Furthermore, the introduction of multifunctional products for improved outcomes is also expected to drive the growth of the surface plasmon resonance market over the forecast period.

As the prevalence of lung cancer, melanoma, and renal cell carcinoma continues to soar worldwide, the adoption of PD-L1 biomarker testing is expected to grow at a healthy pace in the years to come, says Future Market Insights (FMI) in its new market study. Moreover, the report forecasts that the global PD-L1 biomarker testing market will grow in value at a stellar CAGR of 13.1% between 2020 and 2030.